In an era defined by blockbuster product licensing deals and M&A, the greatest partnering attention has been garnered by companies with drug discovery technologies capable of repeatedly generating compounds for a broad spectrum of diseases. Companies with prolific discovery engines are able to strike multiple deals to fund the development of the collaborative candidates as well as their proprietary compounds. Panelists will inform the audience on how to create the greatest value through multiple deals, navigate the pitfalls associated with managing multiple collaborators and describe what it takes to cultivate a hot technology platform in the eyes of partners.

• Educate on how maximum partnering value through the creation of multiple deals based on a core technology platform
• Illustrate how to successfully negotiate the challenges of working with different partners during the licensing phase as well as the candidate development phase
• Discuss maximizing transaction value for both pharma and biotech sides of the deal